References
- de la Monte SD, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983; 43: 3427-33. PMID: 6850649
- Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival. Cancer 1978; 42: 660-8. doi:10.1002/1097-0142(197808)42:2<;660::AID-CNCR2820420237>3.0.CO;2-E
- Zhang D, Wang Z, Shang D, Yu J, Yuan S. Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study. Melanoma Res 2019; 29: 77-84. doi: 10.1097/CMR.0000000000000538
- Chukwueke U, Batchelor T, Brastianos P. Management of brain metastases in patients with melanoma. J Oncol Practice 2016; 12: 536-42. doi: 10.1200/JOP.2016.011882
- Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008; 10: 199-207. doi: 10.1215/15228517-2007-058
- Winston K, Walsh J, Fischer E. Results of operative treatment of intracranial metastatic tumors. Cancer 1980; 45: 2639-45. doi: 10.1002/1097-0142(19800515)45:10<;2639::AID-CNCR2820451025>3.0.CO;2-O
- Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2018; 2: CD011123. doi: 10.1002/14651858.CD011123.pub2
- Hao C, Tian J, Liu H, Li F, Niu H, Zhu B. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. Medicine 2017; 96: e7325. doi: 10.1097/MD.0000000000007325
- Dequen P, Lorigan P, Jansen JP, van Baardewijk M, Ouwens MJ, Kotapati S. Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist 2012; 17: 1376-85. doi: 10.1634/theoncologist.2011-0427
- Rulli E, Legramandi L, Salvati L, Mandala M. The impact of targeted therapies and immunotherapy in melanoma brain metastases: a systematic review and meta-analysis. Cancer 2019; 125: 3776-89. doi: 10.1002/cncr.32375
- van Opijnen MP, Dirven L, Coremans IEM, Taphoorn MJB, Kapiteijn EHW. The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: a systematic review. Int J Cancer 2020; 146: 1479-89. doi: 10.1002/ijc.32696
- Coit DG, Thompson JA, Albertini MR, Barker C, Carson III WE, Contreras C, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. Natl Compr Canc Netw 2019; 17: e1. doi: 10.6004/jnccn.2019.0018
- Long GS, Shivalingam B, Carlino M, Hong, A, Atkinson, V, Kefford, R, et al. Summary of recommendations and practice points: treatment approaches to brain metastases for patients with melanoma. Sydney: Cancer Council Australia; 2019 [updated 2019 Mar 7]; [cited 2021 Jan 28]. Available at: https://wiki.cancer.org.au/australia/Guidelines:Melanoma/Summary_of_treatment_approaches_to_brain_metastases
- Michielin O, Van Akkooi A, Ascierto P, Dummer R, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1884-901. doi: 10.1093/annonc/mdz411
- Hong AM, Waldstein C, Shivalingam B, Carlino MS, Atkinson V, Kefford RF, et al. Management of melanoma brain metastases: evidence-based clinical practice guidelines by Cancer Council Australia. Eur J Cancer 2021; 142: 10-7. doi: 10.1016/j.ejca.2020.10.013
- Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 2005; 31: 256-73. doi: 10.1016/j.ctrv.2005.04.007
- Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-72. doi: 10.1016/S0140-6736(04)16250-8
- Chen JC, Petrovich Z, O’Day S, Morton D, Essner R, Giannotta SL, et al. Stereotactic radiosurgery in the treatment of metastatic disease to the brain. Neurosurgery 2000; 47: 268-81. doi: 10.1097/00006123-200008000-00003
- Brastianos HC, Nguyen P, Sahgal A, Eisenhauer EA, Baetz T, Hanna TP. Association of innovations in radiotherapy and systemic treatments with clinical outcomes in patients with melanoma brain metastasis from 2007 to 2016. JAMA Netw Open 2020; 3: e208204. doi: 10.1001/jamanetworko-pen.2020.8204
- Barbour AB, Jacobs CD, Williamson H, Floyd SR, Suneja G, Torok JA, et al. Radiation therapy practice patterns for brain metastases in the United States in the stereotactic radiosurgery era. Adv Radiat Oncol 2020; 5: 43-52. doi: 10.1016/j.adro.2019.07.012
- Sandler KA, Shaverdian N, Cook RR, Kishan AU, King CR, Yang I, et al. Treatment trends for patients with brain metastases: does practice reflect the data? Cancer 2017; 123: 2274-82. doi: 10.1002/cncr.30607
- Waldstein C, Wang W, Lo S, Shivalingam B, Fogarty GB, Carlino MS, et al. Melanoma brain metastases: the outcome of whole brain radiation therapy in the era of effective systemic therapy. Ther Radiol Oncol 2021; 5: 1-11. doi: 10.21037/tro-21-6
- NCCN. NCCN Guidelines Version 3.2022 Melanoma: Cutaneous US2022. [cited 2022 Mar 15]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
- Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. Eur J Cancer 2020; 126: 159-77. doi: 10.1016/j.ejca.2019.11.015
- Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2011. [cited 2022 Mar 14]. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomsied trials. BMJ 2011; 343: d5928. doi: 10.1136/bmj.d5928
- IBM. Statistical Software for the Social Sciences (SPSS) version 25. Armonk, NY: IBM Corp; 2016.
- Hauswald H, Bernhardt D, Krug D, Katayama S, Habl G, Lorenzo Bermejo J, et al. Whole-brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma - final results of the BRAIN-RT trial. Cancer Manag Res 2019; 11: 4669-76. doi: 10.2147/CMAR.S204729
- Gupta A, Roberts C, Tysoe F, Goff M, Nobes J, Lester J, et al. RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt. Br J Cancer 2016; 115: 1193-200. doi: 10.1038/bjc.2016.318
- Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, et al. Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III trial. J Clin Oncol 2019; 37: 3132-41. doi: 10.1200/JCO.19.01414
- Partl R, Richtig E, Avian A, Berghold A, Kapp KS. Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra-and extracranial metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2013; 85: 662-6. doi: 10.1016/j.ijrobp.2012.06.009
- Samlowski WE, Watson GA, Wang M, Rao G, Klimo Jr P, Boucher K, et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 2007; 109: 1855-62. doi: 10.1002/cncr.22605
- Hauswald H, Dittmar JO, Habermehl D, Rieken S, Sterzing F, Debus J, et al. Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. Radiat Oncol 2012; 7: 130. doi: 10.1186/1748-717X-7-130
- Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117: 1687-96. doi: 10.1002/cncr.25634
- Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012; 117: 227-33. doi: 10.3171/2012.5.JNS111929
- Gieger M, Wu JK, Ling MN, Wazer D, Tsai JS, Engler MJ. Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat Oncol Investig 1997; 5: 72-80. doi: 10.1002/%28SICI%291520-6823%281997%295:2%3C72::AID-ROI5%3E3.0.CO;2-G
- Fife K, Colman M, Stevens G, Firth I, Moon D, Shannon K, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22: 1293-300. doi: 10.1200/JCO.2004.08.140
- Stevens G, Firth I, Coates A. Cerebral metastases from malignant melanoma. Radiother Oncol 1992; 23: 185-91. doi: 10.1016/0167-8140(92)90329-S
- Szyszka-Charewicz B. The effectiveness of brain metastases radiotherapy in patients with melanoma. Nowotwory 2016; 66: 367-74. doi: 10.5603/NJO.2016.0066
- Isokangas OP, Muhonen T, Kajanti M, Pyrhonen S. Radiation therapy of intracranial malignant melanoma. Radiother Oncol 1996; 38: 139-44. doi: 10.1016/0167-8140(95)01691-0
- Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2: 899-906. doi: 10.1002/cam4.140
- Phillips WJ, Lo B, Ong M, Smith T, Song X. Clinical outcomes in patients with melanoma brain metastases at a tertiary cancer center. J Clin Oncol 2019; 37(Suppl 15): e13586. [abstract]. doi: 10.1200/JCO.2019.37.15-suppl.e13586
- Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol 1983; 1: 313-7. doi: 10.1007/BF00165714
- Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 1988; 15: 859-64. doi: 10.1016/0360-3016(88)90118-6
- Cooney RM WB, Altman DG, Abreu MT, Travis SPL. Outcome measurement in clinical trials for ulcerative colitis: toward standardisation. Trials 2007; 8: 17. doi: 10.1186/1745-6215-8-17
- Mak KS, Van Bommel AC, Stowell C, Abrahm JL, Baker M, Baldotto CS, et al. Defining a standard set of patient-centred outcomes for lung cancer. Eur Respir J 2016; 48: 852-60. doi: 10.1183/13993003.02049-2015
- Tugwell P, Boers M, Brooks P, Simon LS, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007; 8: 38. doi: 10.1186/1745-6215-8-38
- Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int 2018; 94: 1053-68. doi: 10.1016/j.kint.2018.08.018
- Tunis SR, Maxwell LJ, Graham ID, Shea BJ, Beaton DE, Bingham CO, et al. Engaging stakeholders and promoting uptake of OMERACT core outcome instrument sets. J Rheumatol 2017; 44: 1551-9. doi: 10.3899/jrheum.161273
- Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: radiation therapy oncology group brain metastases study I and II. Cancer 1980; 45: 679-83. doi: 10.1002/1097-0142(19800215)45:4<;679::AID-CNCR2820450410>3.0.CO;2-J
- Katz HR. The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. Int J Radiat Oncol Biol Phys 1981; 7: 897-906. doi: 10.1016/0360-3016(81)90006-7
- Vlock DR, Kirkwood JM, Leutzinger C, Kapp DS, Fischer JJ. High-dose fraction radiation therapy for intracranial metastases of malignant melanoma: a comparison with low-dose fraction therapy. Cancer 1982; 49: 2289-94. doi: 10.1002/1097-0142(19820601)49:11<;2289::AID-CNCR2820491115>3.0.CO;2-8
- Stridsklev IC, Hagen S, Klepp O. Radiation therapy for brain metastases from malignant melanoma. Acta Radiol Oncol 1984; 23: 231-5. doi: 10.3109/02841868409136017
- Choi KN, Withers HR, Rotman M. Metastatic melanoma in brain. Rapid treatment or large dose fractions. Cancer 1985; 56: 10-5. doi: 10.1002/1097-0142(19850701)56:1<;10::AID-CNCR2820560103>3.0.CO;2-G
- Choi KN, Withers HR, Rotman M. Intracranial metastases from melanoma. Clinical features and treatment by accelerated fractionation. Cancer 1985; 56: 1-9. doi: 10.1002/1097-0142%2819850701%2956:1%3C1::AID-CNCR2820560102%3E3.0.CO;2-X
- Ziegler JC, Cooper JS. Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12: 1839-42. doi: 10.1016/0360-3016(86)90327-5
- Hagen NA, Cirrincione C, Thaler HT, DeAngelis LM. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 1990; 40: 158-60. doi: 10.1212/WNL.40.1.158
- Somaza S, Kondziolka D, Lunsford LD, Kirkwood JM, Flickinger JC. Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg 1993; 79: 661-6. doi: 10.3171/jns.1993.79.5.0661
- Willner J, Bohndorf W. [CNS metastases in malignant melanomas]. [German]. Strahlenther Onkol 1995; 171: 165-73. PMID: 7709333
- Skibber JM, Soong SJ, Austin L, Balch CM, Sawaya RE. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 1996; 3: 118-23. doi: 10.1007/BF02305789
- Gupta G, Robertson AG, MacKie RM. Cerebral metastases of cutaneous melanoma. Br J Cancer 1997; 76: 256-9. doi: 10.1038/bjc.1997.371
- Grob JJ, Regis J, Laurans R, Delaunay M, Wolkenstein P, Paul K, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Eur J Cancer 1998; 34: 1187-92. doi: 10.1016/S0959-8049%2898%2900026-4
- Sampson JH, Carter JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88: 11-20. doi: 10.3171/jns.1998.88.1.0011
- Seung SK, Sneed PK, McDermott MW, Shu HK, Leong SP, Chang S, et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J Sci Am 1998; 4: 103-9. PMID: 9532412
- Lavine SD, Petrovich Z, Cohen-Gadol AA, Masri LS, Morton DL, O’Day SJ, et al. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 1999; 44: 59-66. doi: 10.1097/00006123-199901000-00031
- Konstadoulakis M, Messaris E, Zografos G, Androulakis G. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases: is there a role for surgery? J Neurosurg Sci 2000; 44: 211-8. PMID: 11327290
- Ellerhorst J, Strom E, Nardone E, McCutcheon I. Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases. Int J Radiat Oncol Biol Phys 2001; 49: 93-7. doi: 10.1016/S0360-3016(00)01355-9
- Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 2002; 94: 2265-72. doi: 10.1002/cncr.10426
- Gonzalez-Martinez J, Hernandez L, Zamorano L, Sloan A, Levin K, Lo S, et al. Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience. J Neurosurg 2002; 97(Suppl. 5): 494-8. doi: 10.3171/jns.2002.97.supplement_5.0494
- Mingione V, Oliveira M, Prasad D, Steiner M, Steiner L. Gamma surgery for melanoma metastases in the brain. J Neurosurg 2002; 96: 544-51. doi: 10.3171/jns.2002.96.3.0544
- Noel G, Simon JM, Valery CA, Cornu P, Boisserie G, Ledu D, et al. Linac radiosurgery for brain metastasis of melanoma. Stereotact Funct Neurosurg 2002; 79: 245-55. doi: 10.1159/000070838
- Yu C, Chen JCT, Apuzzo MLJ, O’Day S, Giannotta SL, Weber JS, et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 2002; 52: 1277-87. doi: 10.1016/S0360-3016%2801%2902772-9
- Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg 2002; 96: 552-8. doi: 10.3171/jns.2002.96.3.0552
- Harrison BE, Johnson JL, Clough RW, Halperin EC. Selection of patients with melanoma brain metastases for aggressive treatment. Am J Clin Oncol 2003; 26: 354-7. doi: 10.1097/00000421-200308000-00009
- Conill C, Fernandez-Ibiza J, Malvehy J, Puig S, Sanchez M, Castel T. Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation. Med Clin (Barc) 2004; 122: 413-5. doi: 10.1016/s0025-7753(04)74256-6
- Meier S, Baumert BG, Maier T, Wellis G, Burg G, Seifert B, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 2004; 27: 145-9. doi: 10.1159/000076903
- Morris SL, Low SH, A’Hern RP, Eisen TG, Gore ME, Nutting CM, et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer 2004; 91: 829-33. doi: 10.1038/sj.bjc.6602018
- Radbill AE, Fiveash JF, Falkenberg ET, Guthrie BL, Young PE, Meleth S, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 2004; 101: 825-33. doi: 10.1002/cncr.20447
- Selek U, Chang EL, Hassenbusch SJ, 3rd, Shiu AS, Lang FF, Allen P, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 2004; 59: 1097-106. doi: 10.1016/j.ijrobp.2003.12.037
- Stone A, Cooper J, Koenig KL, Golfinos JG, Oratz R. A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest 2004; 22: 492-7. doi: 10.1081/CNV-200026387
- Koc M, McGregor J, Grecula J, Bauer CJ, Gupta N, Gahbauer RA. Gamma Knife radiosurgery for intracranial metastatic melanoma: an analysis of survival and prognostic factors. J Neurooncol 2005; 71: 307-13. doi: 10.1007/s11060-004-2027-1
- Panagiotou IE, Brountzos EN, Kelekis DA, Papathanasiou MA, Bafaloukos DI. Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome. Neoplasma 2005; 52: 150-8. PMID: 15800714
- Rhomberg W, Eiter H, Boehler F, Saely C, Strohal R. Combined razoxane and radiotherapy for melanoma brain metastases. a retrospective analysis. J Neurooncol 2005; 74: 295-9. doi: 10.1007/s11060-004-7557-z
- Christopoulou A, Retsas S, Kingsley D, Paddick I, Lindquist C. Integration of gamma knife surgery in the management of cerebral metastases from melanoma. Melanoma Res 2006; 16: 51-7. doi: 10.1097/01.cmr.0000198451.26827.b2
- Gaudy-Marqueste C, Regis JM, Muracciole X, Laurans R, Richard MA, Bonerandi JJ, et al. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65: 809-16. doi: 10.1016/j.ijrobp.2006.01.024
- Conill C, Berenguer J, Vargas M, Lopez-Soriano A, Valduvieco I, Marruecos J, et al. Incidence of radiation-induced leukoencephalopathy after whole brain radiotherapy in patients with brain metastases. Clin Transl Oncol 2007; 9: 590-5. doi: 10.1007/s12094-007-0108-2
- Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 2007; 60: 471-81. doi: 10.1227/01.NEU.0000255342.10780.52
- Redmond AJ, Diluna ML, Hebert R, Moliterno JA, Desai R, Knisely JP, et al. Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival. J Neurosurg 2008; 109 (Suppl): 99-105. doi: 10.3171/JNS/2008/109/12/S16
- Carrubba CJ, Vitaz TW. Factors affecting the outcome after treatment for metastatic melanoma to the brain. Surg Neurol 2009; 72: 707-11. doi: 10.1016/j.surneu.2009.03.005
- Ahmad S, Ricco A, Brown R, Hanlon A, Yang J, Feng J, et al. Single institutional experience of stereotactic radiosurgery alone for first brain metastatic event and salvage of second brain metastatic event in a community setting with review of the literature. Front Oncol 2017; 7: 32. doi: 10.3389/fonc.2017.00032
- Rades D, Heisterkamp C, Huttenlocher S, Bohlen G, Dunst J, Haatanen T, et al. Dose escalation of whole-brain radiotherapy for brain metastases from melanoma. Int J Radiat Oncol Biol Phys 2010; 77: 537-41. doi: 10.1016/j.ijrobp.2009.05.001
- Schild SE, Behl D, Markovic SN, Brown PD, Sande JR, Deming RL, et al. Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? Am J Clin Oncol 2010; 33: 633-6. doi: 10.1097/COC.0b013e3181c4c54b
- Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102: 1213-8. doi: 10.1038/sj.bjc.6605622
- Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011; 117: 1697-703. doi: 10.1002/cncr.25631
- Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, et al. Outcome predictors of gamma knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 2011; 114: 769-79. doi: 10.3171/2010.5.JNS1014
- Skeie BS, Skeie GO, Enger PO, Ganz JC, Heggdal JI, Ystevik B, et al. Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged survival. World Neurosurg 2011; 75: 684-91; discussion 598-603. doi: 10.1016/j.wneu.2010.12.054
- Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 2011; 117: 1711-20. doi: 10.1002/cncr.25643
- Bernard ME, Wegner RE, Reineman K, Heron DE, Kirkwood J, Burton SA, et al. Linear accelerator based stereotactic radiosurgery for melanoma brain metastases. J Cancer Res Ther 2012; 8: 215-21. doi: 10.4103/0973-1482.98973
- Koay EJ, Bucheit AD, Jakob JA, Hyun ED, Settle SH, Brown PD, et al. Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma patients with brain metastasis. [abstract]. J Clin Oncol 2012; 30 (15 Suppl 1). doi: 10.1200/jco.2012.30.15_suppl.8584
- Lo SS, Radawski JD, Nelson A, Clarke JW, McGregor JM, Mayr NA, et al. Stereotactic radiosurgery with or without whole brain radiotherapy for patients with one to three melanoma brain metastases. J Radiat Oncol 2012; 1: 73-9. doi: 10.1007/s13566-012-0006-2
- Salvati M, Frati A, D’Elia A, Pescatori L, Piccirilli M, Pietrantonio A, et al. Single brain metastases from melanoma: remarks on a series of 84 patients. Neurosurg Rev 2012; 35: 211-8. doi: 10.1007/s10143-011-0348-z
- Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 2013; 23: 191-5. doi: 10.1097/CMR.0b013e32835f3d90
- Miller D, Zappala V, El Hindy N, Livingstone E, Schadendorf D, Sure U, et al. Intracerebral metastases of malignant melanoma and their recurrences--a clinical analysis. Clin Neurol Neurosurg 2013; 115: 1721-8. doi: 10.1016/j.clineuro.2013.03.019
- Zukauskaite R, Schmidt H, Asmussen JT, Hansen O, Bastholt L. Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma. Melanoma Res 2013; 23: 21-6. doi: 10.1097/CMR.0b013e32835ae915
- Dyer MA, Arvold ND, Chen YH, Pinnell NE, Mitin T, Lee EQ, et al. The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol 2014; 9: 143. doi: 10.1186/1748-717X-9-143
- Marcus DM, Lowe M, Khan MK, Lawson DH, Crocker IR, Shelton JW, et al. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am J Clin Oncol 2014; 37: 580-4. doi: 10.1097/COC.0b013e318280d7be
- Neal MT, Chan MD, Lucas Jr JT, Loganathan A, Dillingham C, Pan E, et al. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg 2014; 82: 1250-5. doi: 10.1016/j.wneu.2013.02.025
- Rades D, Hornung D, Blanck O, Martens K, Khoa MT, Trang NT, et al. Stereotactic radiosurgery for newly diagnosed brain metastases: comparison of three dose levels. Strahlenther Onkol 2014; 190: 786-91. doi: 10.1007/s00066-014-0625-1
- Vecchio S, Spagnolo F, Merlo DF, Signori A, Acquati M, Pronzato P, et al. The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival. Melanoma Res 2014; 24: 61-7. doi: 10.1097/CMR.0000000000000029
- Christ SM, Mahadevan A, Floyd SR, Lam FC, Chen CC, Wong ET, et al. Stereotactic radiosurgery for brain metastases from malignant melanoma. Surg Neurol Int 2015; 6(Suppl 12): S355. doi: 10.4103/2152-7806.163315
- Frakes JM, Figura NB, Ahmed KA, Juan TH, Patel N, Latifi K, et al. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. J Neurosurg 2015; 123: 1261-7. doi: 10.3171/2014.12.JNS141919
- Hauswald H, Stenke A, Debus J, Combs SE. Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma. BMC Cancer 2015; 15: 537. doi: 10.1186/s12885-015-1517-1
- Ivanov PI, Zubatkina IS, Tumarova DI, Andreev GI, Volkov NM. [Analysis of results of Gamma knife radiosurgery for patients with melanoma brain metastases]. [Russian]. Voprosy onkologii 2015; 61: 586-91. doi: УДК616.5-616-831-006;615.47.616-072.7
- Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, et al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg 2015; 123: 395-401. doi: 10.3171/2014.9.JNS141425
- Ostheimer C, Bormann C, Fiedler E, Marsch W, Vordermark D. Malignant melanoma brain metastases: treatment results and prognostic factors - a single-center retrospective study. Int J Oncol 2015; 46: 2439-48. doi: 10.3892/ijo.2015.2970
- Gallaher IS, Watanabe Y, DeFor TE, Dusenbery KE, Lee CK, Hunt MA, et al. BRAF mutation is associated with improved local control of melanoma brain metastases treated with Gamma knife radiosurgery. Front Oncol 2016; 6: 107. doi: 10.3389/fonc.2016.00107
- Patel BG, Ahmed KA, Johnstone PA, Yu HH, Etame AB. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res 2016; 26: 382-6. doi: 10.1097/CMR.0000000000000250
- Rades D, Sehmisch L, Bajrovic A, Janssen S, Schild SE. Comparison of 20x2 Gy and 12x3 Gy for whole-brain irradiation of multiple brain metastases from malignant melanoma. In Vivo 2016; 30: 917-9. doi: 10.21873/in-vivo.11013
- Wolf A, Zia S, Verma R, Pavlick A, Wilson M, Golfinos JG, et al. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neurooncol 2016; 127: 607-15. doi: 10.1007/s11060-016-2072-6
- Acharya S, Mahmood M, Mullen D, Yang D, Tsien CI, Huang J, et al. Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents. Adv Radiat Oncol 2017; 2: 572-80. doi: 10.1016/j.adro.2017.07.003
- All S, Patel H, Keller A, Ramakrishna NR. Initial volumetric response and local control following stereotactic radiosurgery for melanoma brain metastases. Int J Radiat Oncol Biol Phys 2017; 99 (2 Suppl 1): E62-3. doi: 10.1016/j.ijrobp.2017.06.739
- Feng R, Oermann EK, Shrivastava R, Gold A, Collins BT, Kondziolka D, et al. Stereotactic radiosurgery for melanoma brain metastases: a comprehensive clinical case series. World Neurosurg 2017; 100: 297-304. doi: 10.1016/j.wneu.2017.01.014
- Kaidar-Person O, Zagar TM, Deal A, Moschos SJ, Ewend MG, Sasaki-Adams D, et al. The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy. Anticancer Drugs 2017; 28: 669-75. doi: 10.1097/CAD.0000000000000497
- Minniti G, Paolini S, D’Andrea G, Lanzetta G, Cicone F, Confaloni V, et al. Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases. J Neurooncol 2017; 132: 455-62. doi: 10.1007/s11060-017-2394-z
- Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, et al. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 2017; 40: 444-50. doi: 10.1097/COC.0000000000000199
- Pessina F, Navarria P, Tomatis S, Cozzi L, Franzese C, Di Guardo L, et al. Outcome evaluation of patients with limited brain metastasis from malignant melanoma, treated with surgery, radiation therapy, and targeted therapy. World Neurosurg 2017; 105: 184-90. doi: 10.1016/j.wneu.2017.05.131
- Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, et al. The prognostic value of BRAF, C-KIT, and NRAS mutations in melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys 2017; 98: 1069-77. doi: 10.1016/j.ijrobp.2017.03.030
- Xu Z, Lee CC, Ramesh A, Mueller AC, Schlesinger D, Cohen-Inbar O, et al. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. J Neurosurg 2017; 126: 726-34. doi: 10.3171/2016.2.JNS1633
- Diao K, Bian SX, Routman DM, Yu C, Kim PE, Wagle NA, et al. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects. J Neurosurg 2018; 129: 1397-406. doi: 10.3171/2017.7.JNS171286
- Diao K, Bian SX, Routman DM, Yu C, Ye JC, Wagle NA, et al. Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. J Neurooncol 2018; 139: 421-9. doi: 10.1007/s11060-018-2880-y
- Fang P, Boehling NS, Koay EJ, Bucheit AD, Jakob JA, Settle SH, et al. Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. J Neurooncol 2018; 137: 67-75. doi: 10.1007/s11060-017-2695-2
- Gabani P, Fischer-Valuck BW, Johanns TM, Hernandez-Aya LF, Keller JW, Rich KM, et al. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: patterns of care and treatment outcomes. Radiother Oncol 2018; 128: 266-73. doi: 10.1016/j.radonc.2018.06.017
- Kano H, Morales-Restrepo A, Iyer A, Weiner GM, Mousavi SH, Kirkwood JM, et al. Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery. J Neurosurg 2018; 128: 14-22. doi: 10.3171/2016.9.JNS161011
- Kotecha R, Miller JA, Venur VA, Mohammadi AM, Chao ST, Suh JH, et al. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. J Neurosurg 2018; 129: 50-9. doi: 10.3171/2017.1.JNS162797
- Ladwa R, Atkinson V. The changing paradigm of management in melanoma brain metastases. Asia Pac J Clin Oncol 2018; 14: 453-8. doi: 10.1111/ajco.12998
- Matsunaga S, Shuto T, Yamamoto M, Yomo S, Kondoh T, Kobayashi T, et al. Gamma Knife radiosurgery for metastatic brain tumors from malignant melanomas: a Japanese multi-institutional cooperative and retrospective cohort study (JLGK1501). Stereotac Funct Neurosurg 2018; 96: 162-71. doi: 10.1159/000489948
- Tio M, Wang X, Carlino MS, Shivalingam B, Fogarty GB, Guminski AD, et al. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell Melanoma Res 2018; 31: 509-15. doi: 10.1111/pcmr.12682
- Zubatkina I, Ivanov P. Early imaging radioresponsiveness of melanoma brain metastases as a predictor of patient prognosis. J Neurosurg 2018; 129: 354-65. doi: 10.3171/2017.1.JNS162075
- Jardim A, Scott J, Drew Z, Foote MC, Sadasivan AP, Hall B, et al. Extent of surrounding edema does not correlate with acute complications after radiosurgery for melanoma brain metastases. Neurooncol 2019; 145: 581-5. doi: 10.1007/s11060-019-03330-9
- Mastorakos P, Xu Z, Yu J, Hess J, Qian J, Chatrath A, et al. BRAF V600 mutation and BRAF kinase inhibitors in conjunction with Stereotactic radiosurgery for intracranial melanoma metastases: a multicenter retrospective study. Neurosurgery 2019; 84: 868-80. doi: 10.1093/neuros/nyy203
- Tjong MC, Moraes FY, Shultz D. Intracranial control and radionecrosis in melanoma patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol 2019; 139(Suppl 1): S59-60. doi: 10.1016/S0167-8140%2819%2933190-1
- McHugh FA, Kow CY, Falkov A, Heppner P, Law A, Bok A, et al. Metastatic melanoma: surgical treatment of brain metastases - Analysis of 110 patients. J Clin Neurosci 2020; 73: 144-9. doi: 10.1016/j.jocn.2019.12.063
- Pomeranz Krummel DA, Nasti TH, Izar B, Press RH, Xu M, Lowder L, et al. Impact of sequencing radiation therapy and immune checkpoint inhibitors in the treatment of melanoma brain metastases. Int J Radiat Oncol Biol Phys 2020; 108: 157-63. doi: 10.1016/j.ijrobp.2020.01.043